A Dose Escalating Study of HC002 in Healthy Adult Volunteers

NCT06670274 | Completed Phase 1 DMC

• 1 other identifier: HC002-001-24
• Study Type: interventional
• Target: 56
• Locations: 1 country
• Sites: 1

Brief Summary

This is a first-in-human (FIH) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of single and multiple ascending oral doses of HC002 in healthy adult participants.

Conditions

Inflammatory Disease; Autoimmune Diseases

Outcome Measures

Primary Outcomes (3)

• To assess the safety of HC002 by the incidence of adverse events

  SAD- Screening to Day 4 post first dose administration; MAD- screening to Day 11 post first dose administration

• Number of participants with abnormal laboratory values and/or adverse events that are related to treatment

  SAD- Screening to Day 4 post first dose administration; MAD- screening to Day 11 post first dose administration

• Number of participants with changes to the electrocardiogram (ECG) from baseline recorded as adverse events

  SAD- Screening to Day 4 post first dose administration; MAD- screening to Day 11 post first dose administration

Secondary Outcomes (9)

• Plasma PK parameters- Maximum plasma concentration (Cmax) after first dose of HC002

  SAD-Samples will be collected on Day 1 to Day 3 post first dose administration; MAD-Samples collected across 11 timepoints on Day 1 and Day 7 post first dose administration

• Plasma PK parameters- Time for maximum plasma concentration (Tmax) after first dose of HC002

  SAD-Samples will be collected on Day 1 to Day 3 post first dose administration; MAD-Samples collected across 11 timepoints on Day 1 and Day 7 post first dose administration

• Plasma PK parameters-- Area under curve (AUC) after first dose of HC002

  SAD-Samples will be collected on Day 1 to Day 3 post first dose administration; MAD-Samples collected across 11 timepoints on Day 1 and Day 7 post first dose administration

• Plasma PK parameters- Apparent clearance (CL/F) after first dose of HC002

  SAD-Samples will be collected on Day 1 to Day 3 post first dose administration; MAD-Samples collected across 11 timepoints on Day 1 and Day 7 post first dose administration

• Plasma PK parameters- terminal half-life (t1/2) after first dose of HC002

  SAD-Samples will be collected on Day 1 to Day 3 post first dose administration; MAD-Samples collected across 11 timepoints on Day 1 and Day 7 post first dose administration

Study Arms (3)

Part 1 SAD

EXPERIMENTAL

Drug: HC002 SAD

Part 2 MAD

EXPERIMENTAL

Drug: HC002 MAD

Placebo

PLACEBO COMPARATOR

Drug: Placebo

Interventions

HC002 SAD DRUG

Part 1 will enroll 32 participants across 4 cohorts. Route of administration: Oral Dose interval and frequency: Single oral dose range across 4 cohorts.

Part 1 SAD

HC002 MAD DRUG

Part 2 will enroll 24 participants across 3 cohorts. Route of administration: Oral Dose interval and frequency: Once daily for 7 days

Part 2 MAD

Placebo DRUG

Matching placebo will be administered across SAD and MAD

Placebo

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and female participants of 18 to 65 years of age (inclusive)
• Able to read, understand, sign, and date a written informed consent form (ICF) before study participation at Screening
• Male participants must agree to use accepted contraceptive regimens during the study and for a period after the last drug administration.
• Female participants must not be pregnant, intending to become pregnant, or be lactating at any time during the study, and must agree to use accepted contraceptive regimens during the study and for a period after the last drug administration.
• Body mass index (BMI) between 18.0 and 35.0 kg/m2 (inclusive) at screening and body weight ≥ 50 kg.
• Judged to be in good health on the basis of medical history, physical examination, and routine laboratory measurements (i.e., without clinically relevant pathology).
• No clinically significant findings on electrocardiogram (ECG) (12-lead), arterial blood pressure, or heart rate as determined at the discretion of the Investigator.
• Non-smoker, ex-smoker (being defined as persons who completely stopped smoking cigarettes for at least 6 months), or social smoker (being defined as persons who smoke fewer than the equivalent of 10 nicotine containing products per month).
• Able to understand and comply with protocol requirements and instructions and likely to complete the study as planned at Screening and upon admission as per PI's judgement.

You may not qualify if:

• History of any illness or condition that, in the opinion of the Investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant.
• Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with PK of the study drug (except appendectomy, hemorrhoidectomy and simple hernia repair).
• Regular treatment with prescription or nonprescription medications which, at the discretion of the Investigator, may impact either participant safety during the trial or the study objectives. The continued use of prescribed hormonal contraceptives is permitted, provided use has been stable for 3 months.
• Consumption of herbal medications, dietary supplements, and specific fruit products (ie, pomello, Seville orange, and grapefruit).
• History of drug addiction within 2 years before the start of study drug dosing, or a positive test result for drugs of abuse, such as tetrahydrocannabinol (THC), cocaine, amphetamines, barbiturates, benzodiazepines, opiates, methadone, methamphetamines, methylenedioxymethamphetamine (MDMA), and phencyclidine (PCP).
• History of alcohol addiction within 2 years before the start of study drug dosing, positive test for alcohol, or engages in regular consumption of more than 4 units of alcoholic beverages per day or more than 10 units per week (1 unit of alcohol is equivalent to approximately 1 pint \[473 mL\] of beer or lager, 1 glass \[125 mL\] of wine, or 25 mL shot of 40% spirit) before Screening.
• Participation in a clinical study involving administration of either an investigational or a marketed drug within 30 days, 5 half-lives, or until the expected pharmacodynamic effect has returned to Baseline (whichever is longer) before Screening.
• Blood donation or a significant loss of blood within 60 days of the start of study drug dosing or donation of more than 1 unit of plasma within 7 days before Screening.
• Positive result at Screening for any of the following infectious disease tests: hepatitis A virus, hepatitis B virus, hepatitis C virus, and human immunodeficiency virus (HIV-1/-2).
• Illness within 5 days before the start of study drug dosing ("illness" is defined as an acute \[serious or non-serious\] condition \[e.g., the flu or the common cold\]).
• History of any known relevant allergy/hypersensitivity (including allergy to the study drug or its excipients).
• Suicidal tendency, history of or disposition to seizures, state of confusion, and/or a diagnosis with a clinically relevant psychiatric disease.
• Use of immunotherapy within 3 months prior to Screening.
• Abnormal liver function (ALT \> 1.5-times upper limit of normal (ULN) or bilirubin \> 1.5-times ULN).
• Prescence of out-of-range cardiac interval (HR 45 to 100 beats per minute, PR 120 to 220 msec, QRS \< 120 msec, and QTcB ≤ 470 msec \[female\] or ≤ 450 msec \[male\]) on the Screening ECG or other clinically significant ECG abnormalities as determined by the Investigator.

Sponsors & Collaborators

• Holoclara Aus Pty Ltd: lead

Study Sites (1)

CMAX Clinical Research Pty Ltd

Adelaide, South Australia, 5000, Australia

Location

MeSH Terms

Conditions

Autoimmune Diseases

Condition Hierarchy (Ancestors)

Immune System Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 21, 2024
• First Posted: November 1, 2024
• Study Start: November 21, 2024
• Primary Completion: March 31, 2025
• Study Completion: May 7, 2025
• Last Updated: May 30, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

AU (1)